Pharmacogenetics /

• Άλλοι συγγραφείς: Brøsen, Kim, Damkier, Per
• Μορφή: Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Cambridge, MA : Academic Press, 2018.
• Έκδοση: First edition.
• Σειρά: Advances in pharmacology (San Diego, Calif.) ; 83.
• Θέματα: Pharmacogenetics.; Pharmaceutical industry > Technological innovations.; MEDICAL > Pharmacology.; Electronic books.

Πίνακας περιεχομένων:

• Front Cover; Pharmacogenetics; Copyright; Contents; Contributors; Preface; Section I: Cytochrome P450; Chapter One: Cytochrome P450 in Pharmacogenetics: An Update; 1. Introduction; 2. Genetic Variability of CYP Enzymes; 3. CYP1A Subfamily; 3.1. CYP1A2; 4. CYP2A and CYP2B Subfamilies; 4.1. CYP2A6; 4.2. CYP2B6; 5. CYP2C Subfamily; 5.1. CYP2C8; 5.2. CYP2C9; 5.3. CYP2C19; 6. CYP2D6; 7. CYP3A Subfamily; 7.1. CYP3A4; 7.2. CYP3A5; 8. Conclusion; Conflict of Interest; References; Chapter Two: Epigenetics and MicroRNAs in Pharmacogenetics; 1. Introduction; 2. Epigenetics in Pharmacogenetics
• 2.1. Polymorphisms Interacting With DMET Gene Methylation2.2. Polymorphisms Affecting Methylation Machinery; 3. miRNAs in Pharmacogenetics; 3.1. miR-SNPs Affecting Enzymes; 3.2. miR-SNPs Affecting Transporters; 3.3. miR-SNPs Affecting Regulators and miRNA Machinery; 4. Conclusion; Acknowledgments; Conflict of Interest; References; Chapter Three: Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics; 1. Introduction; 1.1. Tamoxifen Metabolism; 1.2. Tamoxifen Transport; 2. CYP2D6 and Tamoxifen Metabolism; 2.1. Studies on Drug-Induced Inhibition of Tamoxifen Metabolism
• 2.2. Limitations of the Pharmacoepidemiological Drug-Drug Interaction Studies2.3. Studies on Pharmacogenetically Reduced Tamoxifen Metabolism; 2.4. Comprehensive Genotyping; 2.5. Use of Tumor-Infiltrated DNA for Genotyping; 3. Perspectives; 3.1. Comprehensive Genotyping; 3.2. Genetically Reduced CYP2D6 Activity May Have Greatest Impact on Tamoxifen Effectiveness in Premenopausal Breast Canc ... ; 3.3. Tamoxifen Transport; 3.4. Other Biomarkers May Impact Tamoxifen Effectiveness; 3.5. Tamoxifen Analogues; 4. Conclusion; Acknowledgments; Conflict of Interest; References; Section II: Methods
• Chapter Four: Imaging in Pharmacogenetics1. Introduction; 2. Imaging Modalities; 3. Absorption; 4. Distribution; 5. Metabolism; 6. Elimination; 7. Conclusion; Conflict of Interest; References; Chapter Five: Pharmacoepidemiology in Pharmacogenetics; 1. Introduction; 2. Study Design; 2.1. Experimental and Observational Cohort Studies; 2.1.1. Calculating Risk-Based Measures of Disease Frequency and Association; 2.1.2. Calculating Rate-Based Measures of Disease Frequency and Association; 2.2. Case-Control Studies; 2.2.1. Strategies for Sampling Controls
• 2.2.2. Calculating Associations in Case-Control Studies2.3. Assessing Interaction in Epidemiologic Studies; 2.3.1. Case-Only Studies; 2.3.2. Biologic Interaction; 3. Bias and Validity; 3.1. Confounding; 3.2. Selection Bias and Matching in Case-Control Studies; 3.3. Information Bias; 3.4. Reverse Causation; 4. Conclusion; Further Reading; Conflict of Interest; References; Section III: Special Themes; Chapter Six: Population Diversity in Pharmacogenetics: A Latin American Perspective; 1. Introduction; 2. Global Distribution of PGx Variants